Generex Biotechnology Corporation, a development stage company, engages in the research, development, and commercialization of drug delivery systems and technologies for metabolic and immunological diseases. It develops a proprietary platform technology for the oral administration of large molecule drugs, including proteins, peptides, monoclonal antibodies, hormones, and vaccines. The company's products include Generex Oral-lyn, an insulin spray formulation used for the treatment of Type-1 and Type-2 diabetes; Glucose RapidSpray, which provides an alternative for people who require additional glucose in their diet, as well as delivers glucose formulation directly into the mouth; BaBOOM! Energy Spray, an instant energy spray designed to increase energy levels for sports, work, study, travel, and overall fatigue; and Crave-NX, a fat-free glucose spray that is used as an aid for dieters. Generex Biotechnology Corporation's under development products include medicinal chewing gum for the treatment of Type-2 diabetes mellitus and obesity; morphine and fentanyl products for breakthrough and postoperative pain; and AE37, an immunotherapeutic vaccine that is in Phase II clinical trials for patients with HER-2/neu positive breast cancer. The company markets its products through distributors and retail chains in Ecuador, Canada, and the United States. It has collaboration with Fertin Pharma A/S for the development of a metformin medicinal chewing gum. The company was founded in 1983 and is based in Toronto, Canada.
Frequently Asked Questions
What is market cap of Generex Biotechnology Corp?
The market cap of Generex Biotechnology Corp is $100.00
What is the 52 week high for Generex Biotechnology Corp?
The 52 week high for Generex Biotechnology Corp is $0.0804.
What is the 52 week low for Generex Biotechnology Corp?
The 52 week low for Generex Biotechnology Corp is $0.00.
What is the 50-day moving average of Generex Biotechnology Corp?
The 50-day moving average of Generex Biotechnology Corp is 0.0001.